Welcome to our dedicated page for Verona Pharma news (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma stock.
Verona Pharma plc (formerly listed on Nasdaq under the symbol VRNA) generated a steady stream of news as a biopharmaceutical company focused on chronic respiratory diseases, particularly chronic obstructive pulmonary disease (COPD). Its news flow has covered the clinical development, regulatory progress and commercialization of its first-in-class COPD maintenance therapy Ohtuvayre (ensifentrine), as well as major corporate events culminating in its acquisition by Merck.
News articles about Verona Pharma include updates on the Phase 3 ENHANCE program for Ohtuvayre, where the drug met primary endpoints in ENHANCE-1 and ENHANCE-2 with statistically significant and clinically meaningful improvements in lung function. The company has also announced multiple scientific presentations at leading respiratory conferences such as the European Respiratory Society (ERS) International Congress and the American Thoracic Society (ATS) Conference, highlighting subgroup analyses on exacerbation rates, dyspnea, quality of life and outcomes in patients with comorbid conditions like cardiac disorders and type 2 diabetes.
Investors following VRNA-related news will also find corporate and financial updates, including quarterly financial results that detail Ohtuvayre net sales, prescription trends, prescriber adoption, and Verona’s funding and debt arrangements. Additional releases have described regulatory milestones, such as approval of Ohtuvayre in Macau through a development partner in Greater China and ongoing regulatory activities for potential marketing applications in other regions.
A key component of Verona Pharma’s news history is its strategic transaction with Merck. Press releases and SEC-related communications outline the July 2025 definitive agreement for Merck to acquire Verona Pharma, subsequent shareholder approval, court sanction of the scheme of arrangement, and Merck’s October 2025 announcement that the acquisition had closed and Verona Pharma had become a wholly owned subsidiary. Coverage of this process includes details of the cash consideration per ordinary share and per ADS and the resulting delisting of VRNA from the Nasdaq Global Market.
This news page serves as an archive of Verona Pharma’s historical announcements, from clinical and commercial milestones for Ohtuvayre to the corporate steps leading to its integration into Merck. Readers interested in the evolution of VRNA, the development of ensifentrine-based therapies, and the transaction that removed Verona Pharma from public markets can use this feed to review the company’s key public communications over time.
The 'Asthma Pipeline Insight – 2023' report by DelveInsight reveals a dynamic landscape in asthma therapies, highlighting over 90 active pharmaceutical players developing more than 95 pipeline treatments. Key companies include GlaxoSmithKline, AstraZeneca, and Verona Pharma. Notably, dexpramipexole received an Innovation Passport from the UK's MHRA and is entering Phase III trials. Additionally, Pulmatrix, Inc. initiated a Phase IIb trial for PUR1900, targeting Allergic Bronchopulmonary Aspergillosis. Olatec Therapeutics secured $40 million in Series A funding to advance dapansutrile into clinical development. This report offers insights into asthma clinical trials, therapeutic assessments, and drug mechanisms.
The Global Inhalable Drugs Market is projected to grow from USD 35.11 billion in 2022 to USD 49.47 billion by 2027, with a CAGR of 7.1%. The report highlights key drivers such as the rising incidence of respiratory diseases and enhanced healthcare infrastructure. Additionally, it examines challenges, including strict regulations for drug approval. Opportunities exist within the development of inhalable drugs and reformulating non-inhaled molecules. The Competitive Quadrant and Ansoff Matrix analyses offer strategic insights for market players. This comprehensive report includes an in-depth market analysis and regulatory scenarios affecting industry dynamics.
Ligand Pharmaceuticals (NASDAQ: LGND) reported its financial results for Q4 and full-year 2022, noting total revenues of $50.4 million in Q4 compared to $56.4 million in 2021. Royalties increased to $22 million due to Pelican platform sales. However, core Captisol sales dropped to $3.3 million, and net loss from continuing operations was $14.5 million, or $0.86 per share. For 2023, Ligand raised its financial guidance, expecting total revenues of $120 to $124 million and adjusted EPS of $3.30 to $3.45. The company anticipates significant revenue growth while maintaining a lean cost structure following the spin-out of OmniAb, which occurred on November 1, 2022.
Verona Pharma (Nasdaq: VRNA) will announce its financial results for Q4 and the full year ending December 31, 2022, on March 7, 2023. A conference call is scheduled for 9:00 a.m. EST for the investment community to discuss these results and provide updates on corporate activities. The company is focused on developing innovative therapies for chronic respiratory diseases, particularly ensifentrine, which has shown promise in improving lung function and reducing COPD exacerbations in Phase 3 clinical trials. The live webcast will be available through their investor page.
The therapeutic respiratory devices market is projected to grow significantly due to increasing cases of respiratory disorders like COPD and asthma, coupled with a rising geriatric population. The market is expected to achieve a CAGR of 9% from 2019 to 2027, with North America leading in revenue generation. The demand has surged post-COVID-19, prompting product innovations and regulatory approvals, such as ABM Respiratory Care’s BiWaze Clear System. However, challenges like high product launch costs and recalls may hinder growth. The report highlights key players, market dynamics, and segmentation by product and application.
The global COPD and asthma devices market reached US$ 40.82 Billion in 2021, with forecasts estimating it will grow to US$ 57.09 Billion by 2027, reflecting a CAGR of 5.75%. Key drivers include an increasing elderly population prone to respiratory disorders, higher smoking rates, and growing healthcare expenditure. Notably, the rise in portable drug delivery devices and automation in healthcare also supports this growth. The report includes insights on market performance, trends, and challenges, while highlighting major players like Verona Pharma. The impact of COVID-19 on the market is also discussed.
Verona Pharma announces positive results from its Phase 3 ENHANCE-1 trial for nebulized ensifentrine, a treatment for chronic obstructive pulmonary disease (COPD). The study met primary and key secondary endpoints, showing significant improvements in lung function, symptoms, and quality of life. Notably, a 36% reduction in moderate to severe COPD exacerbations was achieved over 24 weeks. Ensifentrine demonstrated a favorable safety profile across 48 weeks. The company plans to submit a New Drug Application (NDA) to the FDA in the first half of 2023.
Verona Pharma (Nasdaq: VRNA) announced it will release top-line Phase 3 data from the ENHANCE-1 trial of nebulized ensifentrine on December 20, 2022. This clinical study focuses on the treatment of COPD and aims to demonstrate improvements in lung function. The company will host a webcast to discuss the results at 8:30 a.m. EST. The ENHANCE program includes two studies evaluating ensifentrine's efficacy and safety over 24 weeks. Positive results could position ensifentrine as a pioneering therapy combining bronchodilator and anti-inflammatory properties.
Verona Pharma (Nasdaq: VRNA) reported strengthened financials with access to up to $400 million, including a $150 million debt facility from Oxford Finance, supporting cash runway through 2025. The company anticipates reporting Phase 3 ENHANCE-1 data by the end of 2022 and plans to submit a New Drug Application to the FDA in H1 2023 for ensifentrine, a COPD treatment. The third quarter net loss was $15.6 million, compared to a profit of $11.1 million in Q3 2021. Research and development expenses decreased to $9.8 million from $22.6 million year-over-year.
Ligand Pharmaceuticals (LGND) reported $66.1 million in Q3 2022 revenue, a slight increase from $64.8 million a year prior. Royalty revenue rose 27% to $19.8 million, driven by Kyprolis, Rylaze, and Teriparatide. However, net income fell to $0.4 million ($0.02 per share) from $13.7 million ($0.80 per share) year-over-year. The company increased its 2022 revenue guidance to $184-$189 million, up from $133-$146 million. A significant focus is on the recent spin-off of the OmniAb business, which will impact future reporting. Ligand's cash reserves totaled $121.4 million as of September 30, 2022.